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We report 3 cases of patients with Candida haemulonii isolates that were obtained from hemocultures. In 2 of the 3 cases, iso-
lates exhibited resistance to echinocandins and fluconazole. This is the first report of an echinocandin-resistant species of this
fungus in pediatric patients.
CASE REPORTS
Case 1. A female Down syndrome patient aged 1 year and 7months and diagnosed with cardiopathy (total atrioventricu-
lar septal defect) was hospitalized on 24 November 2009 for total
surgical correction. During surgery, a double-lumen central ve-
nous catheter (CVC) was inserted in the right internal jugular
vein. The patient exhibited good postsurgical recovery; the CVC
was withdrawn and she was discharged from the intensive care
unit (ICU) on 7December 2009. Subsequently, she presentedwith
chylothorax and was readmitted into the ICU 3 days later for
drainage. Her fever was treated with cefepime and then vancomy-
cin. On 14 December 2009, a new CVC was inserted, without any
complications. A blood culture (BC) from the catheter was posi-
tive for coagulase-negative Staphylococcus. A new BC was ob-
tained, and treatment with amphotericin B deoxycholate and
meropenem was initiated. The BC showed growth of Candida
haemulonii.Ultrasonography showed pleural effusion with septa-
tions; surgical debridement was performed to remove necrotic
tissue from the lung apex. On 13 January 2010, a new episode of
sepsis occurred, with the BC testing positive for C. haemulonii.
Amphotericin B deoxycholate was replaced with liposomal am-
photericin B and fluconazole. The patient exhibited good clinical
recovery with this new antifungal treatment and completed 20
days of treatment. She was discharged on 12 February 2010 after
the results of 2 BCs were negative.
Case 2.A 9-year-old female patient was hospitalized on 9 April
2010 with febrile neutropenia following chemotherapy for
Ewing’s sarcoma. She was treated with piperacillin-tazobactam
according to the institutional protocol for febrile neutropenia.
Three days later, she was underwent an odontological evaluation
due to a suspected dental abscess, which confirmed the suspicion;
she subsequently required drainage. On the next day, the antibi-
otic was replaced with imipenem. On the seventh and eighth day
of admission, she had a fever of approximately 38°C. On the 10th
day of admission, an echocardiogram showed an image on the
interatrial septum,which suggested vegetation or a thrombus, and
subsequently, vancomycin treatment was initiated. On the 19th
day of admission, an echocardiography showed an increase in the
size of the vegetation. Antibiotics were maintained through pe-
ripheral venous access (PVA). On the 22nd day, she presented
with fever (38.5°C) and hyperemia at the PVA site together with
pain at the insertion point of the catheter, and a new BC was
collected. The culture showed the presence of C. haemulonii,
probably due to phlebitis at the PVA site. Amphotericin B deoxy-
cholate was administered for 14 days. The patient exhibited reso-
lution of endocarditis after 28 days of antibiotics; the BC was neg-
ative for fungal infection after 14 days of antifungal treatment, and
she was discharged subsequently.
Case 3. A 16-year-old female patient was diagnosed with acute
myeloid leukemia on 18 May 2009. Since then, she had experi-
enced various episodes of febrile neutropenia with multiple hos-
pital admissions to treat several infectious presentations. Subse-
quently, she presented with fever due to phlebitis at the PVA site,
and an ambulatory BC showed growth of C. haemulonii. The pa-
tient did not receive antifungal treatment or present with new
febrile episodes; she was therefore characterized as exhibiting
transient, auto-limited fungemia. The patient continued to follow
her chemotherapy without further complications.
The clinical impact of fungal infections has increased substan-
tially in recent years, particularly in immunocompromised pa-
tients. Candida spp. have emerged as one of the major opportu-
nistic pathogens in such patients. These infections are difficult to
diagnose and cause high levels of morbidity and mortality despite
antifungal therapy (7). This paper describes and discusses findings
in 3 pediatric patients with candidemia caused by C. haemulonii
isolates, in two cases resistant to echinocandins.
Microbiological data. Hemocultures were processed accord-
ing to the standard protocol of the American Society for Microbi-
ology (19) and inoculated at 37°C using a BD Bactec 9120 blood
culture system (Becton, Dickinson, Franklin Lakes, NJ). Colonies
on Sabouraud dextrose agar had a white, smooth, glabrous yeast-
like appearance. Microscopic morphology showed numerous
ovoid-to-globose-shaped budding yeast-like cells. No pseudohy-
phae were produced. A germ tube test was negative, hydrolysis of
urea was negative, growth on cycloheximide medium was posi-
tive, and growth at 37°C was positive (13). Phenotypic identifica-
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tion of the isolates was performed using chromogenic agar
(CHROMagar, Paris, France) and an API 20C AUX system (bio-
Mérieux, Marcy l’Etoile, France), and isolates were identified as
Kodamaea (Pichia) ohmeri in all 3 samples. The API ID code was
approximately 90% for all 3 strains. The Vitek yeast biochemical
card (YBC) (bioMérieux, Durham, NC) system was also used for
identification; this yielded inconclusive results for the first isolate
and identified the other 2 isolates as C. haemulonii.
Molecular data. The isolates were identified using matrix-as-
sisted laser desorption ionization–time of flight (MALDI-TOF)
mass spectrometry. Samples were analyzed in triplicate, using the
Putignani method (12). Scores were satisfactory (above 2) and
identificationwas compatible withC. haemulonii for all 3 samples.
PCR followed by DNA sequencing was used as the gold standard
for identification. The internal transcribed spacer (ITS) and
D1/D2 regions of the ribosomal gene were amplified. For ampli-
fication of the ITS region by PCR, the external primers V9G and
LS266, which specifically amplify this region in fungi, were used,
and primers NL1 andNL4 were used to amplify the D1/D2 region
(5, 18). For sequencing of the amplified products, ITS1 and ITS4
primers (21) were used for the ITS region, and NL1 and NL4
primers were used for the D1/D2 region. Sequencing was per-
formed using the dideoxy chain-terminating method (16), using
an automatic sequencerwith BigDyeTerminator (Applied Biosys-
tems, Foster City, CA). The consensus sequences of the ITS and
D1/D2 regions were aligned using the Sequencher 4.1.4 program
and analyzed by comparison with DNA databases, using the
BLAST tool to identify the species. The gene bank used was the
NCBI database: the 3 samples were identified molecularly as C.
haemulonii. The parameters determined by BLAST analysis were
96% identity and an E value of 6 10175 for the ITS region and
100% identity and an E value of 0.0 for the D1/D2 region. These
results are considered highly reliable for the identification of spe-
cies.
Analysis of the microbiological results indicates that the phe-
notype tests were inadequate to identifyC. haemulonii but that the
molecular tests (PCR and sequencing, as well as MALDI-TOF)
showed 100% agreement. Similar results have been reported by
Stevenson et al. (17).
Antifungigram. Susceptibility assays to the antifungal agents
amphotericin B (Sigma-Aldrich Quimica, Madrid, Spain), flu-
conazole (Pfizer, Madrid, Spain), and micafungin (Mycamine;
Astellas Pharma Inc., Toyama, Japan) were performed, using the
broth microdilution method, in accordance with protocol
M27-A3 of the Clinical and Laboratory Standards Institute (1, 2).
The results (Table 1) showed that the MIC was 1.0 g/ml for
amphotericin B for all 3 samples; for fluconazole, the MICs were
16 g/ml in 2 samples and 32 g/ml in the other sample. For
micafungin, an MIC of 0.5 g/ml was found in 1 sample and an
MIC of 4.0 g/ml in the other 2 samples. These results indicate
that the samples presented a dose-dependent response to flucona-
zole, were resistant tomicafungin, and were sensitive (borderline)
to amphotericin B, according to the CLSI 2008 M27-A3 protocol.
However, although the strains with MICs of 2 g/ml for echi-
nocandins were not considered susceptible, the cutoff for resis-
tance has not yet been established due to a lack of clinical isolates
available from patients with therapeutic failure (11).
Species-specific clinical breakpoints (BPs) have been devel-
oped for fluconazole (8) and micafungin (9) and do not cover
rare species such as C. haemulonii. The BPs used in this re-
search were determined by the Clinical and Laboratory Stan-
dards Institute (1, 2).
In invasive fungemia, Candida albicans is the most common
isolated species, although other non-C. albicans species, such as
Candida tropicalis,Candida krusei,Candida parapsilosis, andCan-
dida glabrata, have a global distribution and are clinically impor-
tant (7, 10). New Candida species have appeared and been recog-
nized as potential pathogens, being described as emerging fungi.
Some of these are closely related to other less rare fungi: Candida
orthopsilosis, Candida metapsilosis, K. ohmeri, and C. haemulonii
are all closely related toC. parapsilosis (6, 20).C. haemulonii is also
related to Candida famata (teleomorph Debaryomyces hansenii)
and Candida guilliermondii (teleomorph Pichia guilliermondii),
which hampers its identification (3). Most Candida species re-
spond well to treatment with azoles, amphotericin, and echino-
candins; however, some species are resistant to these treatments
(10). Laboratory identification of C. haemulonii is important be-
cause there is evidence of decreased susceptibility of this species to
the antifungals typically used in clinics (15).
Clinical presentation of infection by C. haemulonii is charac-
terized by fever, without specificities related to other nosocomial
infections. The interesting feature of these 3 cases ofC. haemulonii
infection was the fact that they did not involve very young chil-
dren, despite having been isolated in a pediatric hospital. Other
predisposing factors frequently reported for this type of candi-
demia are the insertion of a CVC, malignancy, and mechanical
ventilation (MV) (3, 4, 14). The patient in case 1 was hospitalized
in an ICU and therefore had various predisposing factors such as
MV, prolonged use of a CVC, and prolonged use of antimicrobi-
als. In cases 2 and 3, both patients had oncohematologic diseases
and candidemia was clearly associated with phlebitis, with the
PVA site being the entry point.
C. haemulonii is quite resistant to antifungals and appears to be
associated with environmental contamination. Accurate identifi-
cation of this species in clinical samples is of major importance;
however, traditional methods of Candida identification are not
efficient at identifying these rare species (4). Although the API
system is frequently used in the identification of fungi, Lee et al.
have shown that 3 strains of Candida were not adequately identi-
fied by this method, with 2 later being identified as C. haemulonii
and 1 asC. parapsilosis (6). Similarly, Rodero et al. showed in 2002
that isolates ofC. haemulonii could be erroneously identified asK.
ohmeri (86%probability of identification) using the sameAPI 20C
system and the Vitek identification system (14). Published results
have shown that the Vitek 2 system is more consistent than mo-
TABLE 1 Results from the antifungigram of the 3 isolates of Candida
haemulonii
Antifungal
MIC (g/ml) and susceptibility typea
Case 1 Case 2 Case 3
S SDD R S SDD R S SDD R
Fluconazole 32.0 16.0 16.0
Amphotericin 1.0 1.0 1.0
Micafungin 0.5 4.0 4.0
a S, sensitivity; SDD, dose-dependent sensitivity; R, resistance.
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lecular methods in identifying C. haemulonii but also that it can-
not differentiateC. haemulonii from closely related species such as
Candida pseudohaemulonii (4).
In the cases reported here, the identification of C. haemulonii
by the API 20C system was incorrect, with all strains being iden-
tified as K. ohmeri. Upon performance of PCR and sequencing,
these strains were identified as C. haemulonii; MALDI-TOF mass
spectrometry, an easily accomplished method that is increasingly
being used to identify species, also correctly identified these
strains.
This case description also highlights the resistance of C.
haemulonii isolates to antifungals. Previous studies reported that
C. haemuloniiwas resistant to fluconazole and amphotericin B but
susceptible to echinocandins (3, 4, 14). In our report, the isolates
obtained from the 3 patients showed identical patterns of suscep-
tibility, with borderline sensitivity to amphotericin B, dose-
dependent sensitivity to fluconazole, and resistance to the echino-
candins tested (micafungin). Once the genome ofC. haemulonii is
sequenced, molecular studies will be able to identify mutations
that are responsible for this resistance.
Echinocandin treatment was not used in any of the clinical
cases. In case 1, the patient showed improvement only after flu-
conazole was combinedwith amphotericin B treatment. The ther-
apeutic failure of amphotericin B and therapeutic response asso-
ciated with fluconazole could be explained by the fact that the
isolate presented a dose-dependent sensitivity to fluconazole
(used in this case at the maximum dose of 12 mg/kg/day) and
borderline sensitivity to amphotericin B. In cases 2 and 3, it is
likely that the patients had transient candidemia provoked by in-
flammation (barrier loss) at the PVA site, which is considered an
access point to the bloodstream for fungi, because the withdrawal
of the catheter leads to an improvement in phlebitis and a negative
hemoculture. However, in the second case, the patient received
amphotericin B for 14 days, and her improvement may have been
related to this therapy, even if the MIC for this antifungal was a
borderline concentration.
These cases illustrate the importance of correctly identifying
Candida species and the difficulty in identifying C. haemulonii
using phenotypic methods. PCR methods, sequencing, and
MALDI-TOF mass spectrometry presented similar results, con-
firming the identification of this fungus. Susceptibility antifungal
tests are fundamental to the identification of emerging fungi, and
these are the first cases of C. haemulonii isolates with resistance to
echinocandins in a Brazilian pediatric hospital.
ACKNOWLEDGMENT
Mass spectrometry analysis was performed at theDepartment of Biophys-
ics of the Escola Paulista deMedicina, Universidade Federal de São Paulo,
São Paulo, Brazil.
REFERENCES
1. Clinical and Laboratory Standards Institute. 2008. Reference method for
broth dilution antifungal susceptibility testing of yeasts. Approved stan-
dard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2008. Reference method
for broth dilution antifungal susceptibility testing of yeasts. Informa-
tion supplement M27-S3. Clinical and Laboratory Standards Institute,
Wayne, PA.
3. Khan ZU, et al. 2007. Outbreak of fungemia among neonates caused by
Candida haemulonii resistant to amphotericin B, itraconazole, and flu-
conazole. J. Clin. Microbiol. 45:2025–2027.
4. Kim MN, et al. 2009. Candida haemulonii and closely related species at 5
university hospitals in Korea: identification, antifungal susceptibility, and
clinical features. Clin. Infect. Dis. 48:e57–e61.
5. Leaw SN, et al. 2006. Identification of medically important yeast species
by sequence analysis of the internal transcribed spacer regions. J. Clin.
Microbiol. 44:693–699.
6. Lee JS, Shin JH, Kim MN. 2007. Kodamaea ohmeri isolates from patients
in a university hospital: identification, antifungal susceptibility, and
pulsed-field gel electrophoresis analysis. J. Clin.Microbiol. 45:1005–1010.
7. Perlroth J, Choi B, Spellberg B. 2007. Nosocomial fungal infections:
epidemiology, diagnosis, and treatment. Med. Mycol. 45:321–346.
8. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010.
Wild-type MIC distributions, epidemiological cutoff values and species-
specific clinical breakpoints for fluconazole andCandida: time for harmo-
nization of CLSI and EUCAST brothmicrodilutionmethods. Drug Resist.
Updat. 13:180–195.
9. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and
Candida revised: integration of molecular, clinical, and microbiological
data to arrive at species-specific interpretive criteria. Drug Resist. Updat.
14:164–176.
10. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2010.
Variation in Candida spp. distribution and antifungal resistance rates
among bloodstream infection isolates by patient age: report from the
SENTRY Antimicrobial Surveillance Program (2008–2009). Diagn. Mi-
crobiol. Infect. Dis. 68:278–283.
11. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on
micafungin. J. Clin. Microbiol. 48:2373–2380.
12. Putignani L, et al. 2011. MALDI-TOF mass spectrometry proteomic
phenotyping of clinically relevant fungi. Mol. Biosyst. 7:620–629.
13. Rippon JW. 1988. Medical mycology. W.B. Saunders Co., Philadel-
phia, PA.
14. Rodero L, et al. 2002. Transient fungemia caused by an amphotericin
B-resistant isolate of Candida haemulonii. J. Clin. Microbiol. 40:2266–
2269.
15. Ruan S-Y, Kuo Y-W, Huang C-T, Hsiue H-C, Hsueh P-R. 2010. Infec-
tions due toCandida haemulonii: species identification, antifungal suscep-
tibility and outcomes. Int. J. Antimicrob. Agents 35:85–88.
16. Sanger F, Nicklen S, Coulson AR. 1992. DNA sequencing with chain-
terminating inhibitors. Biotechnology 24:104–108.
17. Stevenson LG, Drake SK, Shea Y, Rzelazny AM, Murray PR. 2010.
Evaluation of matrix-assisted laser desorption ionization–time of flight
mass spectrometry for identification of clinically important yeast species.
J. Clin. Microbiol. 48:3482–3486.
18. Sun J, Najafzadeh MJ, Vicente V, Liyan Xi, Hoog GS. 2010. Rapid
detection of pathogenic fungi using loop-mediated isothermal amplifica-
tion, exemplified by Fonsecaea agents of chromoblastomycosis. J. Micro-
biol. Methods 80:19–24.
19. Sutton DA. 2007. Specimen collection, transport, and processing: mycol-
ogy, p 1728–1736. In Murray PR, Baron EJ, Jorgensen JH, Landry ML,
Pfaller MA (ed), Manual of clinical microbiology, 9th ed. ASM Press,
Washington, DC.
20. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC. 2005.
Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Can-
dida parapsilosis groups II and III. J. Clin. Microbiol. 43:284–292.
21. White TJ, Bruns T, Lee S, Taylor JW. 1990. Amplification and direct
sequencing of fungal ribosomal RNA genes for phylogenetics, p 315–322.
In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a
guide to methods and applications. Academic Press, Inc., New York, NY.
Case Report
November 2012 Volume 50 Number 11 jcm.asm.org 3785
